Merck is set to acquire Terns Pharmaceuticals for $6.7 billion, marking its third significant acquisition in the past year as it prepares for the impending patent expiration of its leading cancer drug, Keytruda, in 2028. The deal, valued at $53 per share, represents a 6% premium over Terns’ closing price on Tuesday and is expected to close in the second quarter.

This acquisition underscores Merck’s strategy to enhance its oncology portfolio, particularly with Terns’ promising leukemia treatment that analysts believe could compete with Novartis’ Scemblix. Terns’ stock has surged recently, driven by investor optimism following positive early trial results for the drug, reflecting a broader trend of increased valuations in the biotech sector.

For market professionals, this acquisition highlights the ongoing consolidation in the pharmaceutical industry as companies seek to bolster their pipelines in anticipation of patent cliffs. Investors should monitor how this deal impacts both Merck’s long-term growth trajectory and Terns’ stock performance in the coming months.

Source: cnbc.com